scholarly journals The Connection between Young Students' Physical Health and Their Lifestyle

2015 ◽  
Vol 3 ◽  
pp. 521
Author(s):  
Rita Geske ◽  
Alevtīna Leice ◽  
Madara Miķelsone ◽  
Laila Kudrjavceva
Keyword(s):  
Physical Health ◽  
Vital Capacity ◽  
Eating Habits ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Self Evaluation ◽  
The Status ◽  
Young Students ◽  
Formed Part ◽  
Lipid Parameters

<p><em>The goal of this research is to analyze the status of young students’ physical health and its connection with lifestyle. The research participants were 107 Medical College’s 1<sup>st</sup> year students that formed part of the youth category as it is defined in Latvia, i.e., up until the age of 25. Students’ physical health was evaluated in accordance with Apanasenko’s methods based on investigative anthropometric and functional testing measurements. These measurements included body mass index, vital capacity, strength index, Robinson index and Recovery Heart Rate. Students’ lifestyle habits were determined with the help of questionnaire that included question groups regarding the self-evaluation of health status, health problems and illnesses, eating habits, bad habits, rest and physical activities. During the research, lipid parameters in blood were also measured determining the total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL).</em></p><p> </p>

scholarly journals MEDICAL COLLEGE STUDENTS HEALTH CHANGES DURING THE STUDY PERIOD

2017 ◽  
Vol 3 ◽  
pp. 348
Author(s):  
Rita Geske ◽  
Alevtīna Leice ◽  
Iveta Strode ◽  
Maira Lāce
Keyword(s):  
Physical Health ◽  
Vital Capacity ◽  
Eating Habits ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Self Evaluation ◽  
Medical College ◽  
One Year ◽  
The One ◽  
Lipid Parameters

The goal of this research is to analyze the change of students’ physical health during the one year of studies in context of lifestyle. The research participants were 103 Medical College’s students aged 19 to 56 years. All tests, measurements and questionnaires were done at falls of 2015 and 2016. Students’ physical health was evaluated in accordance with Apanasenko’s methods based on investigative anthropometric and functional testing measurements. These measurements included body mass index, lungs vital capacity, strength index, Robinson index and Recovery Heart Rate. Students’ lifestyle habits were determined with the help of questionnaire that included question groups regarding the self-evaluation of health status, health problems and illnesses, eating habits, and physical activities. During the research, lipid parameters in blood were also measured determining the total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL).

scholarly journals Estimation of the presence of small dense lipoprotein cholesterol in acute ischemic stroke

2015 ◽  
Vol 7 (1) ◽  
Author(s):  
Yasuhiro Manabe ◽  
Ryuta Morihara ◽  
Kosuke Matsuzono ◽  
Yumiko Nakano ◽  
Yoshiaki Takahashi ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Poor Prognosis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Standard Laboratory ◽  
Laboratory Methods ◽  
Established Risk Factor ◽  
The One ◽  
Lipid Parameters

Small dense low-density lipoprotein (sdLDL) is an established risk factor in ischemic heart disease. However, its clinical significance in acute ischemic stroke (AIS) is uncertain. This study evaluates the prognostic value of the presence of sdLDL in patients with AIS by determining whether it contributes to clinical outcome or not. We studied 530 consecutive patients admitted within the first 48 hours after onset of ischemic stroke and 50 corresponding controls. Serum lipid parameters were measured on admission by standard laboratory methods. The percentage of AIS patients with sdLDL was significantly higher than the one of matched controls with sdLDL. Concerning comparisons between AIS patients with or without sdLDL, the percentages of males and patients with histories of smoking, hypertension, and cardiovascular disease were significantly higher in AIS patients with sdLDL. Concerning the grade of severity, modified Rankin Scale (mRS) on discharge was significantly higher in AIS patients with sdLDL. On logistic regression analysis, age (OR=2.29, P3). Our study showed that the presence of sdLDL might be independently associated with a poor prognosis after AIS.

The Relationship of Various Factors in the Pathogenesis of Atherosclerosis

1998 ◽  
Vol 4 (2) ◽  
pp. 105-110 ◽  
Author(s):  
Hüseyin Sönmez ◽  
Selma Süer ◽  
Turgut Ulutin ◽  
Emine Kökoglu ◽  
Nergiz Uçişik
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Plasminogen Activator ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Tissue Type ◽  
Control Group ◽  
Low Density ◽  
Lipid Parameters ◽  
Pai 1

In this study we investigated the levels of lipid parameters, fibronectin, tissue-type plasminogen activator and plasminogen activator inhibitor (t-PA-PAI-1) complex and si alidase in patients with coronary heart disease and a control group. Total cholesterol, triglyceride, low-density lipoprotein (LDL), and very-low-density lipoprotein (VLDL) cholesterol and lipoprotein Lp(a), levels in patients with coronary heart disease were found to be significantly higher than in the control group (p < .001). High-density lipoprotein (HDL) cholesterol levels in patient group were significantly lower than control group (p < .001). Plasma fibronectin and t-PA-PAI-1 complex levels in patients with coronary heart disease were found to be significantly higher than control group (p < .05 and p < .001, respectively). In addition, we found that serum sialidase levels in patients with coronary heart disease were significantly higher than in the control group (p < .001). The electrophoretic mobility of lipoproteins from patients with coronary heart dis ease was found to be greater than those from the control group. As a result Lp(a) may play an important role in the pathogen esis of atherosclerosis by causing foam cell formation because of interacting with LDL or fibronectin and by interfering with the fibrinolytic system because of binding to plasminogen re ceptors. In addition, modifications of Lp(a) (including desi alylation) may effect these events. Key words: Coronary heart disease—tPA-PAI-1 complex-Fibronectin-sialidase-Lipid parameters.

scholarly journals Hepatocurative potentials of methanol extracts/fractions of Tapinanthus bangwensis and Moringa oleifera on carbon tetrachlorideinduced hepatotoxicity in Wistar rats

2020 ◽  
Vol 22 (2) ◽  
pp. 001-014
Author(s):  
G.O. Ihegboro ◽  
A.J. Alhassan ◽  
E. Afor ◽  
C.J. Ononamadu ◽  
T.A. Owolarafe ◽  
...  
Keyword(s):  
Antioxidant Activity ◽  
Wistar Rats ◽  
Moringa Oleifera ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Mineral Elements ◽  
Toxic Substances ◽  
Methanol Extracts ◽  
Lipid Parameters

Bioaccumulation of toxic substances in liver poses a serious threat to its functionality and consequently leads to damage/injury. Medicinal plants have been reported to be effective in the treatment and management of various diseases. The present study is aimed at evaluating the hepatocurative potentials of Tapinanthus bangwensis and Moringa oleifera on carbon tetrachloride-induced hepatotoxicity in Wistar rats. Atomic absorption spectroscopy (AAS) and ultraviolet-visible spectrophotometry were respectively used to assay for mineral elements and antioxidant activity of methanol extracts/fractions of T. bangwensis and M. oleifera. Concentrations of potassium in methanol extract of M. oleifera (MeCE 2) and magnesium in T. bangwensis (MeCE 1) were found to be significantly high (p < 0.05). Concentrations of trace elements were low in the range of 0.07 mg/kg to 0.60 mg/kg. The in vitro lipid peroxidation assay showed that ethylacetate fraction and acetone fraction of T. bangwensis (ETF 1 and ACF 1) respectively exhibited the strongest and lowest antioxidant activity compared to other extracts/fractions. Oral administration of methanol extracts/fractions of T. bangwensis and M. oleifera significantly increased superoxide dismutase (SOD) and catalase (CAT) activities, increased glutathione (GSH) level and decreased malondialdehyde (MDA) level. The liver function indices (or liver biomarkers) such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), albumin, total protein, total and conjugated bilirubin and lipid parameters (low density lipoprotein (LDL-c), cholesterol and triglyceride) were also significantly reduced. However high density lipoprotein (HDL-c) increased in the groups induced and treated with methanol extracts/fractions of T. bangwensis and M. oleifera compared to the group induced but untreated. It can be concluded that the plants possessed hepatocurative potential against CCl - 4 induced hepatotoxicity in Wistar rats Keywords: Bioaccumulation, Hepatotoxicity, Liver biomarkers, Moringa oleifera Tapinanthus bangwensis

scholarly journals Weight Loss and Serum Lipids in Overweight and Obese Adults: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 105 (12) ◽  
pp. 3695-3703
Author(s):  
Bashar Hasan ◽  
Tarek Nayfeh ◽  
Muayad Alzuabi ◽  
Zhen Wang ◽  
Aravind Reddy Kuchkuntla ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Serum Lipids ◽  
Meta Analysis ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Lifestyle Interventions ◽  
Cochrane Database ◽  
Lipid Parameters

Abstract Background Excess adipose tissue is associated with an abnormal lipid profile that may improve with weight reduction. In this meta-analysis, we aimed to estimate the magnitude of change in lipid parameters associated with weight loss in adults who are overweight or obese. Methods We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Scopus from 2013 to September, 2018. We included randomized controlled trials (RCTs) that evaluated interventions to treat adult obesity (lifestyle, pharmacologic and surgical) with follow-up of 6 months or more. Results We included 73 RCTs with moderate-to-low risk of bias, enrolling 32 496 patients (mean age, 48.1 years; weight, 101.6 kg; and body mass index [BMI], 36.3 kg/m2). Lifestyle interventions (diet, exercise, or both), pharmacotherapy, and bariatric surgery were associated with reduced triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) concentrations and increased high-density lipoprotein cholesterol (HDL-C) at 6 and 12 months. The following data are for changes in lipid parameters after 12 months of the intervention with 95% CI. Following lifestyle interventions, per 1 kg of weight lost, TGs were reduced by –4.0 mg/dL (95% CI, –5.24 to –2.77 mg/dL), LDL-C was reduced by –1.28 mg/dL (95% CI, –2.19 to –0.37 mg/dL), and HDL-C increased by 0.46 mg/dL (95% CI, 0.20 to 0.71 mg/dL). Following pharmacologic interventions, per 1 kg of weight lost, TGs were reduced by –1.25 mg/dL (95% CI, –2.94 to 0.43 mg/dL), LDL-C was reduced by –1.67 mg/dL (95% CI, –2.28 to –1.06 mg/dL), and HDL-C increased by 0.37 mg/dL (95% CI, 0.23 to 0.52 mg/dL). Following bariatric surgery, per 1 kg of weight lost, TGs were reduced by –2.47 mg/dL (95% CI, –3.14 to –1.80 mg/dL), LDL-C was reduced by –0.33 mg/dL (95% CI, –0.77 to 0.10 mg/dL), and HDL-C increased by 0.42 mg/dL (95% CI, 0.37 to 0.47 mg/dL). Low-carbohydrate diets resulted in reductions in TGs and increases in HDL-C, whereas low-fat diets resulted in reductions in TGs and LDL-C and increases in HDL-C. Results were consistent across malabsorptive and restrictive surgery. Conclusions Weight loss in adults is associated with statistically significant changes in serum lipids. The reported magnitude of improvement can help in setting expectations, inform shared decision making, and facilitate counseling.

Pemafibrate Tends to have Better Efficacy in Treating Dyslipidemia than Fenofibrate

2020 ◽  
Vol 25 (44) ◽  
pp. 4725-4734
Author(s):  
Haizhou Wang ◽  
Haiou Li ◽  
Yunjiao Zhou ◽  
Jing Liu ◽  
Fan Wang ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Treated Group ◽  
Lipoprotein Cholesterol ◽  
The Public ◽  
Significant Difference ◽  
Comprehensive Search ◽  
Apolipoprotein B48 ◽  
Dichotomous Outcomes ◽  
Lipid Parameters

Aims: To compare the efficacy of pemafibrate (PF) and fenofibrate (FF) in treating dyslipidemia. Methods: A comprehensive search was performed on the public database to identify relevant randomized controlled trials (RCTs), which compared the effects of PF and FF treatment in lipid parameters among patients with dyslipidemia. Mean difference (MD) and 95% confidence intervals (CI) were pooled for continuous outcomes, whereas odds ratio (OR) and 95% CI were calculated for dichotomous outcomes. Results: Three RCTs were included with a total of 744 patients (PF=547 and FF=197). Compared with the FF group (100mg/day), PF group (0.05 to 0.4mg/day) had a better effect on reducing triglycerides (TGs) (MD, -8.66; 95%CI, -10.91 to -6.41), very low-density lipoprotein cholesterol (VLDL-C, MD, -12.19; 95%CI, -15.37 to - 9.01), remnant lipoprotein cholesterol (MD, -13.16; 95%CI, -17.62 to -8.69), apolipoprotein-B48 (ApoB48, MD, -12.74; 95%CI, -17.71 to -7.76) and ApoCIII (MD, -6.25; 95%CI, -11.85 to -0.64). Although a slightly LDL-Cincreasing effect was found in PF-treated group (MD, 3.10; 95%CI, -0.12 to 6.09), the levels of HDL-C (MD, 3.59; 95%CI, 1.65 to 5.53) and ApoAI (MD, 1.60; 95%CI, 0.38 to 2.82) were significantly increased in the PF group. However, no significant difference was found in the level of total cholesterol (MD, 0.01; 95%CI, -1.37 to - 1.39), non-HDL-C (MD, -0.06; 95%CI, -1.75 to 1.63), ApoB (MD, 0.39; 95%CI, -1.37 to 2.15) and ApoAII (MD, 3.31; 95%CI, -1.66 to 8.29) between the two groups. In addition, the incidence of total adverse events (OR, 0.68; 95%CI, 0.53 to 0.86) and adverse drug reactions (OR, 0.36; 95%CI, 0.24 to 0.54) was lower in the PF group than that in the FF group. Conclusions: Pemafibrate tends to have better efficacy in treating dyslipidemia than fenofibrate.

Abstract P62: Efficacy of Ezetimibe 2.5 Milligrams Utilizing a Novel Tablet Splitting Strategy

2011 ◽  
Vol 4 (suppl_1) ◽  
Author(s):  
Lawrence Baruch ◽  
Bhanu Gupta ◽  
Ann Haynos ◽  
Sanjay Agarwal ◽  
Swapna Johnson ◽  
...  
Keyword(s):  
Retrospective Studies ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
P Value ◽  
Lipid Parameter ◽  
Tablet Splitting ◽  
Wide Range ◽  
Daily Dose ◽  
Lipid Parameters

Background: Ezetimibe's excellent tolerability and approximately 20% LDL lowering effect have made it the most commonly prescribed 2 nd line lipid lowering agent after statins. Ezetimibe is available only in a 10 mg form, either as a stand-alone tablet or in combination with simvastatin as ezetimibe/simvastatin (Vytorin). During clinical development, a wide range of ezetimibe doses were evaluated, including 0.25, 1, and 5 mg. A 2.5 mg dose of ezetimibe was never evaluated. Prospective and retrospective studies have demonstrated that splitting a 10 mg ezetimibe tablet, which provides approximately 5 mg of ezetimibe, is clinically equivalent to a whole 10 mg tablet. On the basis of these results, along with others that demonstrated 1 mg of ezetimibe significantly lowered LDL by approximately 13 to 15%, we prospectively randomized patients to either a simvastatin 20 mg tablet or an ezetimibe/simvastatin 10/80 tablet (10 mg ezetimibe plus 80 mg simvastatin) split into 4 to yield an estimated daily dose of ezetimibe 2.5 mg and simvastatin 20 mg. The efficacy of the two strategies on lipid parameters was compared. We selected ezetimibe/simvastatin 10/80 as a means of obtaining 2.5 mg of ezetimibe, as this tablet size can be readily split into 4 relatively equal parts with a commercially available tablet splitter. Study design: Thirty three subjects were randomized to either simvastatin 20 mg or an ezetimibe/simvastatin 10/80 tablet divided into 4. Lipid panels were collected at baseline and after 6 weeks of therapy. Results: Twenty nine of the 33 subjects successfully completed the study. Conclusion: From a comparative effectiveness perspective, ezetimibe 2.5 mg, delivered by splitting an ezetimibe/simvastatin10/80 tablet into 4, provides the greatest value and delivers LDL lowering comparable to full dose ezetimibe 10 mg. This novel tablet splitting strategy may be applicable to other medications and provide significant additional cost-reduction. Lipid Value (mg/dL) ES 2.5/20 * (n=14) Simvastatin 20 (n=15) P (between groups) % change from baseline (p ** ) % change from baseline (p ** ) Low density lipoprotein -44.7 ± 19.0% (<.001) -27.1 ± 22.4% (<.001) 0.03 High density lipoprotein -5.1 ± 7.4% (<.05) -0.7 ± 9.3% (ns) 0.17 Triglycerides -23.3 ± 3.8% (<.01) -11.9 ± 6.0% (.03) 0.18 Total cholesterol -34.2 ± 13.0% (<.001) -19.9 ± 14.6% (<.001) 0.001 Data is expressed as mean ± SD. * ES: Ezetimibe/simvastatin 10/80 tablet split into 4 parts, supplying ezetimibe 2.5 and simvastatin 20. ** P-value for the change in the lipid parameter from the baseline value.

Cholesterol Levels In Patients With Newly Diagnosed Chronic Lymphocytic Leukemia: A retrospective Multicenter Study

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 5292-5292
Author(s):  
Irfan Yavasoglu ◽  
Gokhan Pektas ◽  
Fergün Yilmaz ◽  
Gülsüm Akgün ◽  
Anil Tombak ◽  
...  
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lymphocytic Leukemia ◽  
Lipoprotein Cholesterol ◽  
Control Group ◽  
Low Density Lipoprotein Cholesterol ◽  
Cholesterol Levels ◽  
Lipid Parameters ◽  
Low Cholesterol ◽  
Retrospective Multicenter Study

Abstract Low cholesterol levels can be detected in solid tumors and hematological malignancies such as muliple myeloma. Moreover chloesterol levels reduced in some experimental studies of patients with chronic lymphocytic leukemia (CLL). In this retrospective multicenter study, lipid levels were retrospectively evaluated in 420 (264 male and 256 female with mean age 64 ± 11 years) patients with newly diagnosed CLL, according to the International CLL study group. 71 (28 male and 43 female with mean age 55 ± 9 years) healthy subjects as control group were included to this study. Lipid parameters such as total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), very low-density lipoprotein-cholesterol (VLDL-C), and triglyceride levels were measured with enzymatic/ calorimetric method and Architect C800 instrument. Low-density lipoprotein-cholesterol (LDL-C) levels were calculated according to Friedwald formula. Lipid parameters between two groups were compared with Mann-Whitney U test. A value of p< 0.05 was accepted as statistically significant. According to Binet classification, 60% of patients were in stage A, while 25% of them were in stage C. In CLL patients, the levels of TC, HDL-C, and LDL-C were lower than those of control group (p=0.001). There was no significantly difference for triglyceride and VLDL-C levels between two groups (p>0.05) (Table-1). The levels of TC, LDL-C, and HDL-C in the patients with stage C were lower than those of both stage A and stage B (Table-2). Low cholesterol levels in patients with CLL may occur due to increased use of cholesterol by lymphocytes.Table-1Lipid parameters in control group and CLL patientsCLL (N:420)Control (N:71)P valueTC (mg/dl)175±41217±36<0.001HDL-C (mg/dl)37±1153±14<0.001LDL-C (mg/dl)108±30131±29<0.001Triglyceride (mg/dl)140±71147±68>0.05VLDL-C (mg/dl)31±1731±17>0.05Table 2Lipid parameters in the patients according to Binet classificationStage A (n:255)Stage B(n:61)Stage C(n:104)P valueTC(mg/dl)183±38179±43156±40<0.001HDL-C(mg/dl)40±1237±1232±12<0.001LDL-C (mg/dl)112±28110±3398±30<0.001Triglyceride (mg/dl)141±76136±53141±68>0.05VLDL-C(mg/dl)30±1535±3331±13>0.05 Disclosures: Sonmez: Novartis Pharmaceuticals Corporation, Turkey: Membership on an entity’s Board of Directors or advisory committees.

Fatty liver is an integral feature of familial combined hyperlipidaemia: relationship with fat distribution and plasma lipids

2006 ◽  
Vol 112 (2) ◽  
pp. 123-130 ◽  
Author(s):  
Martijn C. G. J. Brouwers ◽  
Monique A. L. Bilderbeek-Beckers ◽  
Anna M. Georgieva ◽  
Carla J. H. van der Kallen ◽  
Marleen M. J. van Greevenbroek ◽  
...  
Keyword(s):  
Fatty Liver ◽  
Plasma Lipids ◽  
Low Density Lipoprotein ◽  
Subcutaneous Fat ◽  
Density Lipoprotein ◽  
Fat Distribution ◽  
Representative Subset ◽  
Hepatic Fat ◽  
Subcutaneous Adiposity ◽  
Lipid Parameters

Overproduction of VLDL (very-low-density lipoprotein) particles is an important cause of FCHL (familial combined hyperlipidaemia). It has been shown recently that VLDL production is driven by the amount of hepatic fat. The present study was conducted to determine the prevalence of fatty liver in relation to the different fat compartments and lipid parameters in FCHL. A total of 68 FCHL patients, 110 normolipidaemic relatives and 66 spouses underwent ultrasound of the abdominal region to estimate the amount of subcutaneous, visceral and hepatic fat. Skinfold callipers were used to measure subcutaneous fat of the biceps, triceps, subscapular and supra-iliacal regions. Fatty liver was observed in 18% of the spouses, 25% of the normolipidaemic relatives and 49% of the FCHL patients. After adjustment for age, gender and body mass index, the prevalence of fatty liver was significantly higher in FCHL patients compared with spouses [OR (odds ratio), 3.1; P=0.03], and also in the normolipidaemic relatives compared with spouses (OR, 4.0; P=0.02), whereas no differences were observed between FCHL patients and normolipidaemic relatives (OR, 0.8; P=0.58). In the normolipidaemic relatives and FCHL patients combined, both visceral fat mass and subcutaneous abdominal fat were independent predictors of fatty liver (P<0.001 for both fat compartments; FCHL status corrected). Of interest, fatty liver stages were correlated with both VLDL-apoB (apolipoprotein B) and VLDL-triacylglycerols (triglycerides) in a representative subset (n=69) of patients and relatives (r2=0.12, P=0.006; and r2=0.18, P=0.001 respectively). These results show that fatty liver is a central aspect of FCHL, i.e. patients and normolipidaemic relatives. Both visceral and subcutaneous adiposity contribute to its 3–4-fold higher risk in FCHL.

Sign in / Sign up

Export Citation Format

Share Document